ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  nintedanib
Find trials that include:  Any drugs shown
Results 1-13 of 13 for your search:
Start Over
Nintedanib (BIBF 1120) in Mesothelioma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
Nintedanib and Capecitabine in Treating Patients with Refractory Metastatic Colorectal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 265514, NCI-2015-00223, NCT02393755
Nintedanib, Idarubicin Hydrochloride, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1507016193, NCI-2016-00754, NCT02665143
Nintedanib in Treating Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Previously Treated with Bevacizumab
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00033060, NCI-2013-00455, NCT01669798
Nintedanib in Treating Patients with Metastatic HER2-Negative Inflammatory Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0464, NCI-2015-00506, NCT02389764
Nintedanib in Treating Patients with Locally Advanced or Metastatic Neuroendocrine Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259114, NCI-2015-00238, NCT02399215
Nintedanib Compared with Placebo in Treating against Radiation-Induced Pneumonitis in Patients with Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: I 257814, NCI-2015-00704, NCT02452463
Nintedanib and Prednisone in Reducing Radiation-Induced Pneumonitis in Patients with Thoracic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 14-167, NCI-2015-01232, NCT02496585
Nintedanib in Treating Patients with Malignant Pleural Mesothelioma That Is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-010, NCI-2015-01412, 1506014121, NCT02568449
Cisplatin, Docetaxel, and Nintedanib before Surgery in Treating Patients with Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0844, NCI-2014-02091, NCT02225405
Nintedanib and Bevacizumab in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB15108, NCI-2016-01656, NCT02835833
Nintedanib in Treating Patients with Metastatic Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Mutations in Nintedanib-Targeted Genes
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201412116, NCI-2014-02625, 14-x346, NCT02299141
Start Over